What did Roche report for 2025?

Sales grew 1.7% to CHF 61.5 billion and net income jumped 50% to CHF 13.8 billion. Pharmaceuticals grew, while Diagnostics fell about 3% due to China’s volume procurement. Results were slightly below consensus, so guidance and the higher dividend proposal are now the key focus for investors.

What is Roche’s 2026 outlook?

Management targets mid single digit sales growth and high single digit core EPS in 2026. The plan assumes steady demand in oncology and immunology, cost control, and manageable pricing pressure in China. Execution in Diagnostics and timely product launches will be the main drivers for achieving the targets.

What is the proposed Roche dividend and yield?

The board proposed CHF 9.80 per share. At a recent share price around CHF 338.30, that implies a forward dividend yield of roughly 2.9%. The trailing payout was CHF 9.70, and the payout ratio is about 67.5%, supported by strong operating and free cash flow.

Is Roche stock expensive right now?

The shares trade near 28.8x earnings and 5.8x sales, with a free cash flow yield around 4.7% and return on equity near 19%. That reflects a quality premium. Upside from here likely depends on Diagnostics stabilization and the success of new product launches in 2026.

When is today’s earnings announcement?

Roche is scheduled to report today at 16:30 UTC, which is 17:30 CET. Investors should watch comments on the 2026 guidance, China pricing in Diagnostics, and details on the proposed CHF 9.80 dividend and cash allocation for the year.

Global Market Insights

ROG.SW Stock Today: January 29 Profit +50%, 2026 Outlook, Dividend Up

ByDanny Kontos January 29, 2026January 29, 2026

Roche stock is in focus in Switzerland today as the group reports 2025 results and sets its 2026 outlook. For 2025, sales rose 1.7% to CHF 61.5 billion and net income jumped 50% to CHF 13.8 billion. Management plans a higher dividend of CHF 9.80 and targets mid single digit sales growth with high single digit core EPS in 2026. With ROG.SW near recent highs, investors will weigh guidance, cash returns, and trends in Diagnostics. Results were slightly below consensus, so commentary on China and launches will be key.